India Globalization Capital, Inc. (NYSE: IGC) Announces Alzheimer’s Drug Candidate Targeting Aβ Proteins

 

  • More than 5.3 million people in the U.S. have Alzheimer’s disease, which has no effective cure or substantial treatment
  • India Globalization Capital’s IGC-ADI drug candidate targets proteins associated with the buildup of lesions in the brain
  • The company acquired exclusive rights to a patent, based on University of South Florida studies supporting THC’s role in inhibiting Aβ plaque production

Alzheimer’s disease now affects over 5.3 million people in the United States, imposing an estimated economic cost of $236 billion. There has been no effective treatment to slow down or reverse its effects. That may be about to change, as India Globalization Capital, Inc. (NYSE MKT: IGC) launched a press release (http://cnw.fm/v0IFP) detailing its work on a drug candidate, IGC-ADI, that targets the buildup of lesions in the brain associated with Alzheimer’s. Given that the number of cases is expected to double over the next two decades, a lack of a cure or other mitigating therapy is concerning. However, the company expects to soon begin trials that may yield promising new treatments.

The unconventional nature of this drug candidate is that it is tetrahydrocannabinol (THC)-based. Low doses of THC have been found to inhibit amyloid beta peptide (Aβ plaque) production. This protein is believed to cause plaque to form in the cerebral cortex and hippocampus. Phosphorylated Tau proteins make up another type of lesion, called a neurofibrillary tangle, that is also linked to AD. The Aβ proteins normally cleared away by biological processes are unregulated in Alzheimer’s patients, and therefore build up into…

Read More >>

More from CannabisNewsWire

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.net

Leave a Reply